title: Poxviral-based vaccine elicits immunologic responses in prostate cancer patients.
abstract: Prostvac is a poxviral-based vaccine designed to target prostate-specific antigen (PSA) in prostate cancer patients. Recently, the potential toxicity and immunological impact of this immunotherapy were reviewed in the context of new clinical data. Our findings suggest that Prostvac is safe and elicits anticancer immune responses, both alone and in combinatorial approaches.
authors.affiliation: Laboratory of Tumor Immunology and Biology; National Cancer Institute; National Institutes of Health; Bethesda, MD USA ; Genitourinary Malignancies Branch; National Cancer Institute; National Institutes of Health; Bethesda, MD USA.
authors.forename: Ravi A
authors.initials: RA
authors.lastname: Madan
authors.affiliation: Laboratory of Tumor Immunology and Biology; National Cancer Institute; National Institutes of Health; Bethesda, MD USA.
authors.forename: Christopher R
authors.initials: CR
authors.lastname: Heery
authors.affiliation: Laboratory of Tumor Immunology and Biology; National Cancer Institute; National Institutes of Health; Bethesda, MD USA ; Genitourinary Malignancies Branch; National Cancer Institute; National Institutes of Health; Bethesda, MD USA.
authors.forename: James L
authors.initials: JL
authors.lastname: Gulley
keywords: T-cell responses; antigen spreading; cancer vaccine; immune response; prostate cancer
references.citation: Nat Med. 2012 Aug;18(8):1254-61
references.pmid: 22842478
references.citation: J Clin Oncol. 2009 Oct 1;27(28):4685-92
references.pmid: 19720923
references.citation: Oncologist. 2010;15(9):969-75
references.pmid: 20798195
references.citation: J Clin Oncol. 2010 Mar 1;28(7):1099-105
references.pmid: 20100959
references.citation: Cancer Immunol Immunother. 2010 May;59(5):663-74
references.pmid: 19890632
references.citation: Expert Opin Investig Drugs. 2009 Jul;18(7):1001-11
references.pmid: 19548854
references.citation: Eur J Cancer. 2013 Apr;49(6):1273-9
references.pmid: 23266046
references.citation: Cancer Immunol Res. 2014 Feb;2(2):133-41
references.pmid: 24778277
references.citation: Clin Cancer Res. 2011 Feb 15;17(4):907-17
references.pmid: 21106727
references.citation: Cancer Immunol Immunother. 2013 Sep;62(9):1521-31
references.pmid: 23836412